Although this off‐target interaction did not solve the problem of therapeutic resistance related to double‐mutated EGFR, it has proved to be beneficial by inhibiting EGFR and HER‐2, a crucial aberrant receptor of other types of tumors such as breast cancer [24, 25]. The gene discussed is EGFR; the disease is breast cancer.